Topics

NanoView Biosciences and Alfatest Enter into Distribution Agreement

09:00 EDT 3 Oct 2019 | Businesswire
NanoView Biosciences, Inc.

NanoView Biosciences, Inc., and Alfatest today announced an exclusive distribution agreement for NanoView’s ExoView™ platform in Italy.

“We believe that scientists in Italy will be excited to have access to NanoView’s unique exosome characterization technology to open up new avenues of research into extracellular vesicles,” said Valentino Polchi, General Manager of Alfatest. “Our team will be working closely with NanoView as we introduce this technology to an important new European market.”

The ExoView platform provides high-resolution sizing, counting, and phenotyping of exosomes at the individual extracellular vesicle level. The molecular cargo carried by exosomes has potential for diagnostic, prognostic, and even therapeutic use for a broad range of diseases. The ExoView platform requires minimal sample input, no sample prep or purification, and little hands-on time. It can be used directly with complex biological samples.

“It is an honor to work with the Alfatest team for our first distribution agreement in Europe,” said Jerry Williamson, CEO of NanoView Biosciences. “We have been intently focused on expanding access to the ExoView platform to help accelerate exosome research around the world with our one-of-a-kind technology for accurately characterizing extracellular vesicles.”

The ExoView platform is designed For Research Use Only. It is not for use in diagnostic procedures.

About NanoView Biosciences

NanoView Biosciences, a Boston-based, privately-held company, is focused on enabling life science researchers to better understand the biological role of exosomes and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The company’s proprietary product, the ExoView™ system, was designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision medicine. ExoView is a high-throughput, cost-effective analysis platform that is easy to use and does not require purification or large sample volumes to accurately analyze exosomes.

www.nanoviewbio.com

Michelle Linn
Bioscribe
Phone: 774-696-3803
Email: michelle@bioscribe.com

NEXT ARTICLE

More From BioPortfolio on "NanoView Biosciences and Alfatest Enter into Distribution Agreement"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...